Collegium Pharmaceutical, Inc. Retained Earnings
Collegium Pharmaceutical, Inc. (COLL) had Retained Earnings of -$101.68 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$101.68M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$86.63M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$101.13M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$118.09M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$101.68M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$86.63M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$101.13M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$118.09M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$149.60M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$161.58M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$164.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$176.53M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$185.87M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$205.48M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$233.19M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$265.13M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$285.76M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$298.77M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$281.34M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$274.14M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$274.60M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$269.41M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$256.34M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$231.31M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$239.35M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$312.20M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$333.15M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$340.11M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$351.39M 10-Q · filed 2020-08-05 |
| 2020-03-31 | -$359.45M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$359.90M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$357.70M 10-Q · filed 2019-11-06 |
| 2019-06-30 | -$351.59M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$346.88M 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$337.18M 10-K · filed 2020-02-27 |
| 2018-09-30 | -$346.26M 10-Q · filed 2018-11-08 |
| 2018-06-30 | -$329.76M 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$316.70M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$298.05M 10-K · filed 2019-02-27 |
| 2017-09-30 | -$280.65M 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$267.38M 10-Q · filed 2017-08-09 |
| 2017-03-31 | -$246.26M 10-Q · filed 2017-05-10 |
| 2016-12-31 | -$223.18M 10-K · filed 2018-03-07 |
| 2016-09-30 | -$195.63M 10-Q · filed 2016-11-10 |
| 2016-06-30 | -$169.18M 10-Q · filed 2016-08-11 |
| 2016-03-31 | -$144.66M 10-Q · filed 2016-05-11 |
| 2015-12-31 | -$129.01M 10-K · filed 2017-03-10 |
| 2015-09-30 | -$119.48M 10-Q · filed 2015-11-12 |
| 2015-06-30 | -$110.12M 10-Q · filed 2015-08-12 |
| 2015-03-31 | -$105.45M 10-Q/A · filed 2015-07-17 |
| 2014-12-31 | -$101.75M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |